MSK
- About
- Browse Articles
-
Special Issues
- Pioneering strategies for overcoming bacterial drug resistance (2026)
- Advancing microbial engineering through synthetic biology (2025)
- Host-associated microbiome (2024)
- Bacterial regulatory mechanisms for the control of complex cellular mechanisms (2023)
- Two years into COVID-19 pandemic: Where are we? (2022)
- Collections
- For Contributors
- Policies
- E-Submission
- About
- Browse Articles
-
Special Issues
- Pioneering strategies for overcoming bacterial drug resistance (2026)
- Advancing microbial engineering through synthetic biology (2025)
- Host-associated microbiome (2024)
- Bacterial regulatory mechanisms for the control of complex cellular mechanisms (2023)
- Two years into COVID-19 pandemic: Where are we? (2022)
- Collections
- Policies
- For Contributors
Articles
- Page Path
- HOME > J. Microbiol > Volume 46(1); 2008 > Research Support, Non-U.S. Gov't
-
Research Support, Non-U.S. Gov't
- Isolation of Quinupristin/Dalfopristin-Resistant Streptococcus agalactiae from Asymptomatic Korean Women
- Hye Ran Nam , Hak Mee Lee , Yeonhee Lee
-
Journal of Microbiology 2008;46(1):108-111.
DOI: https://doi.org/10.1007/s12275-007-0217-1
Culture Collection of Antimicrobial Resistant Microbes, Department of Biology, Seoul Women’s University, Seoul 139-774, Republic of Korea
-
Corresponding author:
Yeonhee Lee , Tel: 82-2-970-5664,
Abstract
Seven Streptococcus agalactiae isolates were obtained from the vagina of 80 asymptomatic women. Three of these isolates showed multi-drug resistant (MDR) phenotypes: two isolates were resistant to clarithromycin, clindamycin, erythromycin, and tetracycline; and one isolate was resistant to clarithromycin, clindamycin, erythromycin, tetracycline, and quinupristin/dalfopristin. There was no clonal relationship among the MDR isolates. This is the first report of quinupristin/dalfopristin-resistant S. agalactiae.
-
Cite this Article
- Cite this Article
-
- Close
- Download Citation
- Close
- Related articles
-
TOP
